Porton Advanced Solutions
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A leading global ATMP CRO and CDMO providing end-to-end services for cell and gene therapy development and manufacturing.
OncologyImmunologyRare Diseases
Technology Platform
Proprietary LV-SMART® suspension production platform for scalable lentiviral vector manufacturing and the AI-guided AAVantage® platform for novel AAV capsid discovery and optimization.
Opportunities
Significant growth opportunity from the global expansion of cell and gene therapy pipelines, especially in China, and increasing demand for integrated, end-to-end CDMO services for complex ATMPs.
Expansion into allogeneic cell therapies and in vivo gene editing represents a key future growth vector.
Risk Factors
Intense competition from established global CDMOs (e.g., Lonza, Catalent) and other Asian CDMOs, potential regulatory complexities in operating across China and U.S.
jurisdictions, and reliance on capital expenditure to scale capacity ahead of demand.
Competitive Landscape
Competes with global CDMOs like Lonza, Catalent, and Charles River Laboratories, as well as specialized CGT CDMOs like Oxford Biomedica and WuXi Advanced Therapies. Differentiation is based on its integrated China/U.S. footprint, strong NMPA regulatory track record, and proprietary vector production platforms (LV-SMART®, AAVantage®).